Covington Leads AstraZeneca To Buy $1B Pfizer Genetics Biz
AstraZeneca PLC said on Friday that its Alexion arm has agreed to buy the early-stage rare disease gene therapy portfolio from its U.S. rival Pfizer Inc. in a deal worth up to...To view the full article, register now.
Already a subscriber? Click here to view full article